Urapidil, a dual-acting antihypertensive agent: Current usage considerations

Area of Science:

• Pharmacology and Therapeutics
• Cardiovascular Medicine
• Nephrology

Background:

• A significant number of patients with hypertension do not achieve target blood pressure (BP) levels despite various treatments.
• Combination therapy with multiple antihypertensive agents is often necessary for effective BP management.
• Alpha-1-adrenoreceptor antagonists (alpha-blockers) are a class of antihypertensive drugs with BP-lowering effects comparable to other classes.

Purpose of the Study:

• To review the role of alpha-blockers in hypertension management.
• To highlight the specific properties and clinical applications of urapidil as an antihypertensive agent.
• To discuss urapidil's efficacy as second-line therapy and its potential benefits beyond BP reduction.

Main Methods:

• Review of existing studies on alpha-blockers in hypertension.
• Focus on urapidil's pharmacological profile, including its dual mechanism of action (alpha-blocking and central sympatholytic effects).
• Evaluation of clinical evidence for oral and intravenous urapidil in various settings.

Main Results:

• Alpha-blockers are effective as add-on therapy for inadequately controlled hypertension.
• Urapidil demonstrates efficacy and tolerability as a second-line treatment for hypertension.
• Urapidil may improve glucose and lipid metabolism and has applications in hypertensive crises, perioperative hypertension, pre-eclampsia, and potentially acute stroke.

Conclusions:

• Alpha-blockers, particularly urapidil, are valuable in managing hypertension, especially when BP targets are not met.
• Urapidil offers additional metabolic benefits and has a broad range of clinical uses, including emergency situations.
• The review underscores the importance of considering urapidil in diverse clinical scenarios for effective hypertension management.